Trial site
Baoding
Baoding, ChinaNot linked to an institution yet
- 12running trials
- 2closed trials
- 0trials confirmed by the site in the last 60 days
- –languages not stated
The site has not confirmed any trial yet.
Running trials
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· PHASE3· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· PHASE3· Source
Recruiting
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
NCT07613424· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277· PHASE3· Source
Active, not recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814· PHASE3· Source
Active, not recruiting
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692· PHASE3· Source
Active, not recruiting
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399· PHASE3· Source
Active, not recruiting
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
NCT05246514· PHASE2· Source
Active, not recruiting
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· PHASE3· Source
Active, not recruiting
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425· PHASE3· Source
Active, not recruiting
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496· PHASE3· Source
Active, not recruiting
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235· PHASE3· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Researchers
No researcher is linked here yet.
Report an error